advertisement
Abstract #11448 Published in IGR 6-3
Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies
Konstas AGP; Banyai L; Blask K-D; Vath J; Kozobolis VP; Trub PR; Tsironi S; Maloutas S; Teus MA; Stewart WCJournal of Ocular Pharmacology and Therapeutics 2004; 20: 375-382
PURPOSE: The aim of this study was to evaluate the efficacy and safety in ocular hypertensive or open-angle glaucoma patients changed to a latanoprost/timolol fixed combination (LTFC) from previous therapy. METHODS: We employed a retrospective, multicenter, active-controlled study evaluating patients who had a previous therapy substituted with LTFC and had a 3-month follow-up. RESULTS: In the 168 patients included in the trial, LTFC reduced the intraocular pressure (IOP) after switching from previous therapies: timolol (22.8 ± 3.5 to 19.0 ± 3.9 mmHg, N = 49, p < 0.001), latanoprost (21.2 ± 3.8 to 18.3 ± 2.5 mmHg, N = 54, p < 0.001), and a dorzolamide/timolol fixed combination (20.9 ± 2.4 to 20.0 ± 2.7 mmHg, N = 32, p = 0.03). In switching from a latanoprost and timolol unfixed combination, the pressure changed from 18.3 ± 3.8 to 18.9 ± 3.0 mmHg (N = 33, p = 0.38). LTFC was persistent in 131 (78%) patients within the 3-month treatment period. The most common adverse event with LTFC was conjunctival hyperemia, which occurred in patients not previously treated with latanoprost therapy (N = 16, 10%). CONCLUSIONS: LTFC generally provides reduced IOP and limited side effects when substituted for other common glaucoma therapies, while providing similar pressure when switched from its own individual components.
Dr. W.C. Stewart, Pharmaceutical Res. Network, L.L.C., 1639 Tatum Street, Charleston, SC 29412-2464, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
